Salivary Antioxidant Status in Patients with Oral Lichen Planus: Correlation with Clinical Signs and Evolution during Treatment with Chamaemelum nobile

Table 1

Median (interquartile range) data for TAC1, TAC2, CUPRAC, and FRAP at baseline (T1) and four weeks after (T2) in placebo and treatment groups.

Analyte	Placebo			Treatment
	T1	T2		T1	T2
Flow rate, ml/min	4.7 (1.4–7.8)	4.1 (2.0–7.5)	0,427	3.6 (1.5–9.0)	5.1 (1.2–7.5)	0.4672
Xerostomy	19 (11–30)	22 (13–33)	0.457	24 (12–34)	22 (12–31)	0.048
TAC1, mmol/L	0,201 (0,136–0,299)	0,233 (0,150–0,393)	0,390	0,288 (0,166–0,404)	0,278 (0,209–0,445)	0,477
TAC2, mmol/L	0,400 (0,258–0,589)	0,421 (0,223–0,522)	0,972	0,457 (0,295–0,513)	0,397 (0,276–0,526)	0,946
CUPRAC, mmol/L	0,130 (0,088–0,255)	0,191 (0,116–0,359)	0,401	0,199 (0,113–0,348)	0,225 (0,149–0,408)	0,391
FRAP, mmol/L	0,323 (0,090–0,467)	0,406 (0,197–0,848)	0,039	0,392 (0,195–0,685)	0,464 (0,298–0,568)	0,781